Healthcare / Medical DevicesKSE
$13600.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$126.0B
P/E
43.7x
↑EV/EBITDA
14.4x
↑ROE
2.4%
↑Gross Margin
31.1%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.6%
FCF CAGR
—
FCF margin
-1.6%
FCF / Net income
-0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $102.61B · net income $2.82B · FCF $-1.59B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $102.61B | $102.61B | $101.76B | $112.44B | $118.18B |
| Net Income | $2.82B | $2.82B | $5.23B | $9.23B | $8.46B |
| EBITDA | $9.27B | $9.27B | $10.76B | $15.28B | $13.65B |
| EPS | 311.00 | 311.00 | 554.00 | 980.00 | 901.00 |
| Gross Margin | 31.1% | 31.1% | 30.4% | 32.0% | 29.4% |
| Operating Margin | 6.9% | 6.9% | 6.2% | 10.1% | 8.8% |
| Net Margin | 2.8% | 2.8% | 5.1% | 8.2% | 7.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.03 | 0.08 | 0.07 |
| Current Ratio | 1.79 | 1.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.59B | $-1.59B | $5.65B | $1.66B | $960.0M |
| Returns | |||||
| ROE | 2.4% | 2.4% | 4.5% | 8.1% | 7.9% |
| Valuation | |||||
| P/E | 43.73 | 43.73 | 25.96 | 14.61 | 16.48 |
| EV/EBITDA | 14.35 | 14.35 | 12.85 | 9.24 | 10.57 |
| P/B | 1.07 | 1.07 | 1.17 | 1.18 | 1.31 |
| Growth & Yield | |||||
| Revenue Growth | 0.8% | 0.8% | -9.5% | -4.9% | — |
| EPS Growth | -43.9% | -43.9% | -43.5% | 8.8% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
57.1%
EPS terminal req.
$1206.77
Spread vs growth
-101.0%
5Y implied EPS CAGR
36.2%
EPS terminal req.
$1460.20
Spread vs growth
-80.1%
10Y implied EPS CAGR
22.4%
EPS terminal req.
$2351.66
Spread vs growth
-66.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.4%
Start / end P/E
26.4x → 43.7x
EPS bridge
554.00 → 311.00
Residual
-28.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.